JGC
MREO

J. Goldman & Co’s Mereo BioPharma MREO Stock Holding History

J. Goldman & Co’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-52,384
Closed -$142K – 552
2025
Q2 		$142K Sell
52,384
-27,003
-34% -$65.2K ﹤0.01% 420
2025
Q1 		$179K Hold
79,387
– – ﹤0.01% 437
2024
Q4 		$278K Sell
79,387
-175,503
-69% -$690K 0.01% 395
2024
Q3 		$1.05M Buy
254,890
+27,000
+12% +$112K 0.03% 293
2024
Q2 		$820K Sell
227,890
-50,698
-18% -$164K 0.02% 320
2024
Q1 		$919K Buy
278,588
+116,588
+72% +$395K 0.03% 276
2023
Q4 		$374K Sell
162,000
-283,485
-64% -$542K 0.02% 276
2023
Q3 		$575K Buy
445,485
+94,500
+27% +$125K 0.02% 268
2023
Q2 		$463K Sell
350,985
-256,515
-42% -$298K 0.02% 296
2023
Q1 		$429K Buy
607,500
+297,000
+96% +$267K 0.02% 275
2022
Q4 		$233K Hold
310,500
– – 0.01% 304
2022
Q3 		$267K Buy
310,500
+175,500
+130% +$215K 0.01% 325
2022
Q2 		$151K Sell
135,000
-82,051
-38% -$63.6K 0.01% 315
2022
Q1 		$243K Buy
217,051
+149,550
+222% +$193K 0.01% 314
2021
Q4 		$108K Sell
67,501
-173,912
-72% -$348K 0.01% 321
2021
Q3 		$584K Sell
241,413
-385,008
-61% -$1.02M 0.03% 267
2021
Q2 		$1.99M Buy
626,421
+563,654
+898% +$1.89M 0.08% 224
2021
Q1 		$212K Sell
62,767
-397,284
-86% -$1.4M 0.01% 396
2020
Q4 		$1.65M Buy
460,051
+16,534
+4% +$41.4K 0.08% 207
2020
Q3 		$1.16M Buy
+443,517
New +$1.3M 0.08% 206

Other funds holding MREO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

J. Goldman & Co's MREO Position: Q3 2025 in Review

J. Goldman & Co sold out of Mereo BioPharma (MREO) in Q3 2025, closing a stake of 52,384 shares — an estimated $142K sold.

J. Goldman & Co first reported a position in MREO in Q3 2020 and held it in 20 quarters. The position peaked at $1.99M in Q2 2021. 84 funds tracked by Wall St. Rank hold MREO as of Q3 2025.

  • J. Goldman & Co reported no remaining Mereo BioPharma position as of Q3 2025 after selling out during the quarter.
  • J. Goldman & Co sold 52,384 Mereo BioPharma shares in Q3 2025, an estimated $142K.
  • J. Goldman & Co first reported a position in Mereo BioPharma in Q3 2020 and held it in 20 quarters.
  • J. Goldman & Co's Mereo BioPharma position peaked at $1.99M in Q2 2021.
  • 84 funds tracked by Wall St. Rank held Mereo BioPharma as of Q3 2025.

Based on J. Goldman & Co's 13F filing for Q3 2025, filed 14 Nov 2025.